Cargando…
Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance
BACKGROUND: Emergence of resistance against integrase inhibitor raltegravir in human immunodeficiency virus type 1 (HIV-1) patients is generally associated with selection of one of three signature mutations: Y143C/R, Q148K/H/R or N155H, representing three distinct resistance pathways. The mechanisms...
Autores principales: | Fun, Axel, Leitner, Thomas, Vandekerckhove, Linos, Däumer, Martin, Thielen, Alexander, Buchholz, Bernd, Hoepelman, Andy I. M., Gisolf, Elizabeth H., Schipper, Pauline J., Wensing, Annemarie M. J., Nijhuis, Monique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755036/ https://www.ncbi.nlm.nih.gov/pubmed/29304821 http://dx.doi.org/10.1186/s12977-017-0384-z |
Ejemplares similares
-
Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis
por: Messiaen, Peter, et al.
Publicado: (2013) -
HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
por: Fun, Axel, et al.
Publicado: (2011) -
Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses
por: Marije Hofstra, Laura, et al.
Publicado: (2014) -
Digital PCR as a tool to measure HIV persistence
por: Rutsaert, Sofie, et al.
Publicado: (2018) -
HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)